ロード中...
Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial
Nimotuzumab (N) is a humanized anti‐epidermal growth factor receptor monoclonal antibody. This prospective, single‐armed, open label phase II study was conducted to evaluate the efficacy and safety of the combination of paclitaxel (T)/cisplatin (P) with nimotuzumab (N) as first‐line treatment in adv...
保存先:
| 出版年: | Cancer Sci |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4832869/ https://ncbi.nlm.nih.gov/pubmed/26797530 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12894 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|